
    
      A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination
      with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or
      Metastatic Renal Cell Carcinoma (RCC)
    
  